REGENXBIO Adds Investment Veteran Greg Ciongoli to Board

Ciongoli, the founder of Adiumentum Capital Management, brings extensive experience in capital allocation and biotechnology investment to the firm. His background includes a 16-year tenure at The Baupost Group, where he oversaw investments across diverse sectors. Currently, he holds leadership roles at Atara Biotherapeutics and Zymeworks Inc., expertise that REGENXBIO CEO Curran Simpson cited as vital for the company's next phase of growth.

The board reshuffle follows years of service from Karabelas, who joined in 2015, and Bennett, who was appointed in 2021. Chairman Ken Mills credited both outgoing directors with helping stabilize the company during its pivotal development period. For REGENXBIO, the appointment arrives as the company advances a late-stage pipeline, including treatments for Duchenne muscular dystrophy and retinal diseases, aiming to move from a research-focused entity to a commercial-stage powerhouse.